Epigenetics refers to the study of changes in gene activity that occur without altering the underlying DNA sequence. Epigenetic changes…
(5 min read)
Exploring Epigenetic DNA Modifications
read more
Stay Updated! Subscribe to The Primer
Share
Explore the Potential of Peptide Therapies
The market for peptide therapies is rapidly becoming a pivotal area in precision medicine.
4 min read
Breaking Down Drug Metabolism
When popping a pill, how often do we think about what happens next—to the pill or our bodies? Maybe we assume the body welcomes any extra help to soothe our headaches or control our blood pressure. This article looks into the mystery of what comes after the swallow....
Swallowing a Biological Drug?
Over the past two decades, biological drugs — drugs composed of proteins produced by living cells — have become the safest, most effective top sellers within the pharmaceutical industry. Approved to treat a variety of diseases, including rheumatoid arthritis,...
Parp1 Inhibitor Takes on Pancreatic Cancer
PARP1 inhibitors are back in the headlines after Astra Zeneca’s (Cambridge, England) and Merck’s (Kenilworth, New Jersey) Lynparza approval by FDA to treat pancreatic cancer patients based on the positive Phase III results. Pancreatic cancer is a notoriously difficult...
Hope On The Horizon For Huntington’s
No question about it, Huntington’s disease (HD) is cruel. In the beginning, sufferers of this fatal neurodegenerative disorder experience involuntary movement and mood disturbance, most often in the form of depression. As the disease progresses, patients lose the...
From Drug Discovery to Approval: Phase IV
We previously focused on the final stage of clinical testing, Phase III trials, where drug developers assess the safety and efficacy of their drug in large patient groups. At the end of Phase III, drug developers face the moment of truth: does the study data support...
From Drug Discovery to Approval: Phase III
Our recent article explored the riskiest part of the human clinical trials pathway: Phase II. About 70% of drugs that enter Phase II never make it out. Most often, it’s because they fail to demonstrate effectiveness. Even making it to Phase III is no guarantee of...
From Drug Discovery to Approval: Phase I/II
Every drug in clinical use today, from the latest CAR-T treatment to older cholesterol-lowering statins, share one thing in common: they have all successfully navigated the rigorous clinical trials process. This is no small feat, as only ~10% of the drugs that enter...
Biotech Primer is your go-to source for interactive training across the biotechnology, pharmaceutical, molectular diagnositcs, and medical device sectors. Explore a range of in-depth biotech courses designed to deepen your understanding of key principles and applications in the field.